Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2023 Jun 9;23(1):610.
doi: 10.1186/s12913-023-09503-7.

Impact of PSA testing on secondary care costs in England and Wales: estimates from the Cluster randomised triAl of PSA testing for Prostate cancer (CAP)

Joanna C Thorn  1 , Emma L Turner  2 , Eleanor I Walsh  2 , Jenny L Donovan  2 , David E Neal  3 , Freddie C Hamdy  3 , Richard M Martin  2 , Sian M Noble  4
Affiliations
Randomized Controlled Trial

Impact of PSA testing on secondary care costs in England and Wales: estimates from the Cluster randomised triAl of PSA testing for Prostate cancer (CAP)

Joanna C Thorn et al. BMC Health Serv Res. .

Abstract

Background: Screening men for prostate cancer using prostate-specific antigen (PSA) testing remains controversial. We aimed to estimate the likely budgetary impact on secondary care in England and Wales to inform screening decision makers.

Methods: The Cluster randomised triAl of PSA testing for Prostate cancer study (CAP) compared a single invitation to men aged 50-69 for a PSA test with usual care (no screening). Routinely collected hospital care data were obtained for all men in CAP, and NHS reference costs were mapped to each event via Healthcare Resource Group (HRG) codes. Secondary-care costs per man per year were calculated, and cost differences (and population-level estimates) between arms were derived annually for the first five years following randomisation.

Results: In the first year post-randomisation, secondary-care costs averaged across all men (irrespective of a prostate cancer diagnosis) in the intervention arm (n = 189279) were £44.80 (95% confidence interval: £18.30-£71.30) higher than for men in the control arm (n = 219357). Extrapolated to a population level, the introduction of a single PSA screening invitation could lead to additional secondary care costs of £314 million.

Conclusions: Introducing a single PSA screening test for men aged 50-69 across England and Wales could lead to very high initial secondary-care costs.

Keywords: Budget impact analysis; Cost-effectiveness analysis; Economic evaluation; Prostate cancer screening; Secondary care.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Flow of men through the study
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Heidegger I. PSA screening—a matter of debate? Magazine of European Medical Oncology. 2019;12(3):244–248. doi: 10.1007/s12254-019-00524-9. - DOI
    1. Mishra SC. A discussion on controversies and ethical dilemmas in prostate cancer screening. J Med Ethics. 2021;47(3):152–158. doi: 10.1136/medethics-2019-105979. - DOI - PubMed
    1. Heijnsdijk EA, Bangma CH, Borràs JM, de Carvalho TM, Castells X, Eklund M, et al. Summary statement on screening for prostate cancer in Europe. Int J Cancer. 2018;142(4):741–746. doi: 10.1002/ijc.31102. - DOI - PubMed
    1. Martin RM, Donovan JL, Turner EL, Metcalfe C, Young GJ, Walsh EI, et al. Effect of a low-intensity PSA-based screening intervention on prostate cancer mortality: the CAP randomized clinical trial. JAMA. 2018;319(9):883–895. doi: 10.1001/jama.2018.0154. - DOI - PMC - PubMed
    1. Ilic D, Djulbegovic M, Jung JH, Hwang EC, Zhou Q, Cleves A, et al. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. BMJ. 2018;362:k3519. doi: 10.1136/bmj.k3519. - DOI - PMC - PubMed

Publication types

Substances